Brad Bolzon, Ph.D., serves as Chairman and Managing Director at Versant Ventures, where he leads the firm. See sector focus and contact routes.
Brad Bolzon, Ph.D., serves as Chairman and Managing Director at Versant Ventures, where he leads the firm, architects its strategy, and oversees operations across North America and Europe. With 18 years as a venture capitalist and 13 years in global pharmaceutical leadership, he focuses the firm’s investment thesis on biotech and digital health innovations globally. Versant typically backs companies from seed to exit, notably supporting breakthrough biotechnology firms around the globe. Bolzon’s portfolio includes notable companies such as CRISPR Therapeutics, BlueRock Therapeutics, Amira, and Okairos, which have collectively generated close to $1.7 billion in returns for stakeholders. The firm operates distinctive in-house drug-discovery engines alongside its venture platform, backing seed-stage biotech ventures like CRISPR and BlueRock through to exit. While specific check sizes and lead/follow behavior are not detailed in available sources, Bolzon’s track record emphasizes long-term, high-impact investments in science-driven healthcare companies. No public writing or distinctive point-of-view statements by Bolzon are cited in the provided results.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Menlo Park.
Investors like Brad Bolzon · Full investor directory · Investor access · Company funding database